FDA Determines Regulatory Review Period for Singulair Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of the medication Singulair, as required by law, following a submission to the US Department of Commerce for the extension of the patent claiming the human drug product.